Science 37, Inc. (SNCE)
| Market Cap | 219.90M |
| Revenue (ttm) | 72.57M |
| Net Income (ttm) | -40.73M |
| Shares Out | 116.35M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 259,498 |
| Open | 2.01 |
| Previous Close | 2.03 |
| Day's Range | 1.86 - 2.01 |
| 52-Week Range | 1.61 - 15.10 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 6.38 (+237.6%) |
| Earnings Date | Aug 11, 2022 |
About SNCE
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orch... [Read more...]
Financial Performance
In 2021, Science 37's revenue was $59.60 million, an increase of 151.42% compared to the previous year's $23.70 million. Losses were -$94.33 million, 197.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SNCE stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 237.57% from the latest price.
News
Science 37 Reports Second Quarter 2022 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results ...
Science 37 to Report Second Quarter 2022 Financial Results on August 11, 2022
RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report second quarter 2022 fi...
Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates
Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months Almost three in four (73%) oncology research executive...
Science 37® to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in...
Science 37® to Present at the William Blair 42nd Annual Growth Stock Conference
RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in ...
Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials
New offering provides access to patients beyond the existing site network can be implemented in four weeks. New offering provides access to patients beyond the existing site network can be implemented i...
Science 37® Extends Leadership in Decentralized Clinical Trial Market with NextGen SaaS Release to Fully Orchestrate ...
New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying stakeholder journeys, increasing compliance, and generating the highest-quality data for a...
Science 37 Reports First Quarter 2022 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results f...
Science 37 to Report First Quarter 2022 Financial Results on May 9, 2022
RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 fi...
Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial methodologies to the industry's largest therapeutic area. Addition of Dr. Beg provides Science 37 with e...
Science 37 Reports Fourth Quarter and Full Year 2021 Financial Results
RESEARCH TRIANGLE PARK, N.C., March 22, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results...
Science 37 to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
RESEARCH TRIANGLE PARK, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report fourth quarter and fu...
New Science 37® CNS Survey Confirms Growing Trend in Clinical Trials Landscape
Within CNS indications, data suggest Agile Clinical Trials™ and decentralized approaches will become more prevalent in 2022 and beyond Within CNS indications, data suggest Agile Clinical Trials™ and dec...
Science 37®'s Operating System Receives ISO Certification for Information Security Management
ISO 27001 certification and ISO 27701:2019 extension demonstrate Science 37's commitment to quality, cybersecurity and privacy management ISO 27001 certification and ISO 27701:2019 extension demonstrate...
Science 37® to Present at the Cowen 42nd Annual Health Care Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in...
Science 37®'s Community Provider Network Grows Sixfold, Reaching Nearly 28 Million Patients
Since January 2021, Science 37's community provider network has added nearly 35,000 physician-providers to enable agile clinical trial execution. Since January 2021, Science 37's community provider netw...
Science 37® and physIQ Collaborate to Enhance Clinical Trial Data Collected from Connected Devices
Collaboration will yield objective, predictive, and real-time digital measures—supplementing clinical trial digital endpoints collected from biosensors Collaboration will yield objective, predictive, an...
Worldwide Clinical Trials and Science 37® Partner to Advance Agile Clinical Trials™ and Accelerate Study Timelines
Science 37's Operating System to enhance Worldwide Clinical Trials' approach to decentralized clinical trials for faster enrollment, better retention, and more representative solutions Science 37's Oper...
Science 37® Furthers Global Expansion with Capabilities in China and Russia to Advance Decentralized Clinical Trials ...
Science 37 enhances its Operating Systems, adding ability to deploy its technology platform into China and Russia and strengthening global capabilities to execute clinical trials and accelerate developm...
Science 37® Reveals a Pivotal Shift in the Clinical Trials Landscape
New data suggest that, for the first time, research sponsors and CROs plan to run more agile or hybrid clinical trials than traditional, site-based studies New data suggest that, for the first time, res...
Science 37 Reports Quarterly Financial Results for the Period Ended September 30, 2021
LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Operating System for today's more agile clinical trials, today reported its financial results ...
Science 37 to Report Third Quarter 2021 Financial Results on November 15, 2021
LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Operating System for today's more agile clinical trials, today announced it will report third quarter 2021 fi...
Science 37® and CMIC Announce Partnership to Advance Decentralized Clinical Trials in Japan/APAC and Speed Drug Devel...
LOS ANGELES and TOKYO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Science 37, the Operating System for today's more agile clinical trials, and CMIC HOLDINGS Co., Ltd. (“CMIC”), the largest CRO in Japan today ann...
Science 37® and 3H Medi Solution Collaborate to Enable Decentralized Clinical Trials in Japan and Accelerate Patient ...
LOS ANGELES and TOKYO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Science 37, the Operating System for today's more agile clinical trials and 3H Medi Solution Inc., a clinical trials solution leader in Japan tod...
Science 37 makes Nasdaq debut
Science37Nasdaq Clinical research company Science 37 CEO David Coman joins the Yahoo Finance's Adam Shapiro to discuss the company's SPAC debut. Don't Miss: Valley of Hype: The Culture That Built Elizab...